HOUSTON, Texas — January 22, 2026 — Leads & Copy — Plus Therapeutics, Inc. (NASDAQ: PSTV), a healthcare company focused on precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, has provided a business update, highlighting clinical progress for REYOBIQ and commercialization efforts for CNSide in the U.S.
Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics, stated that the company’s two main goals for 2026 are scaling up commercial operations for CNSide and preparing for the pivotal trial of REYOBIQ. A recently completed $15 million offering will support progress in these areas and extend the company’s cash runway through 2027.
REYOBIQ Clinical Program:
- The company aims to define the optimal dose and interval for REYOBIQ in the ReSPECT-LM Phase 2 trial, with data expected in Q3 2026.
- Enrollment is being completed in the ReSPECT-GBM Phase 2 trial for glioblastoma. An end-of-phase meeting with the FDA is planned to align on the pivotal trial design, with data anticipated in Q4 2026.
- Commercial manufacturing scale-up for REYOBIQ is underway.
- Enrollment is set to begin in the ReSPECT-PBC pediatric brain cancer Phase 1 trial.
CNSide Commercial Rollout:
- The goal is to secure coverage for 150 million U.S. lives under multiple commercial payor agreements.
- Medicare and Medicaid coverage is being pursued.
- The company aims to achieve a commercial order rate exceeding 1,250 tests per year.
- A portfolio of additional CSF tumor characterization tests will be launched to expand the CNSide testing platform.
REYOBIQ (rhenium Re186 obisbemeda) is an injectable radiotherapy designed to deliver targeted high-dose radiation to CNS tumors. It is being evaluated for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer in the ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC clinical trials. The ReSPECT-GBM trial is supported by the National Cancer Institute (NCI), and ReSPECT-LM is funded by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). The ReSPECT-PBC clinical trial is supported by a $3 million grant from the U.S. Department of Defense’s Peer Reviewed Cancer Research Program.
CNSide Diagnostics, LLC, a subsidiary of Plus Therapeutics, Inc., develops and commercializes laboratory-developed tests like CNSide®, which identifies tumor cells that have metastasized to the central nervous system. The CNSide® CSF Assay Platform allows quantitative analysis of cerebrospinal fluid to improve the management of patients with leptomeningeal metastases.
Plus Therapeutics, Inc., headquartered in Houston, Texas, is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for cancers of the central nervous system. The company combines image-guided local beta radiation and targeted drug delivery approaches to advance a pipeline of product candidates in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM).
Leptomeningeal metastases (LM) affect the fluid-lined structures of the central nervous system and occur in approximately 5% of patients with metastatic cancer. Common sources include breast cancer, lung cancer, and melanoma. Median survival is typically 2-6 months.
Plus Therapeutics hosted a conference call and webcast on January 22, 2026, at 9:00 a.m. ET to discuss the business update.
Investor Contact:
CORE IR
investor@plustherapeutics.com
Source: Plus Therapeutics
